Company / Shareholders' Equity
Celldex Therapeutics, Inc. Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$527.2M
FY2025
5-year range
$326.2M / $747.0M
FY2021-FY2025
Trend
-29.4%
vs FY2024
Sector context
#102 of 160
Health Care
What the data says
At $527M, Celldex Therapeutics, Inc.'s shareholders' equity ranks #102 of 160 in the Health Care sector. Shareholders' Equity has fluctuated over the past 10 years, ranging from $94M in FY2019 to $747M in FY2024.
Based on SEC 10-K filings.
$527M in FY2025 with a 5-year CAGR of +20.3%.
Improved from $429M to $527M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +17.4%
- 5-Year CAGR
- +20.3%
- 10-Year CAGR
- -
Sector benchmark
#102 of 160 in Health CareTop 64% of 160This company $527.2M Sector average $5.0B
▼
-89.5% below sector average
Key checks
Key Insights
- 5-year CAGR of +20.3%, indicating consistent growth.
- In FY2025, shareholders' equity decreased 29.4% year-over-year.
- Ranks #102 out of 160 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.40 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $527.2M | -29.4% |
| FY2024 | $747.0M | +74.1% |
| FY2023 | $429.2M | +31.6% |
| FY2022 | $326.2M | -22.2% |
| FY2021 | $419.5M | +100.4% |
| FY2020 | $209.4M | +122.7% |
| FY2019 | $94.0M | -64.6% |
| FY2018 | $265.4M | +12.3% |
| FY2017 | $236.4M | -10.9% |
| FY2016 | $265.4M | -8.5% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026